Larkberget Intangible Assets

What does Larkberget do? CombiGene AB specializes in developing treatments for neurological disorders using gene therapy vectors. The company's platform delivers combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. CombiGene focuses on an epilepsy treatment utilizing an adeno-associated virus (AAV) vector carrying transgenes for NPY and its Y2 receptor. The firm targets neurological and psychiatric diseases in humans and animals through its gene therapy approach. CombiGene AB's products are developed for the treatment of epilepsy and other neurological conditions. The company's platform is designed to deliver multiple therapeutic elements simultaneously via gene therapy vectors. The firm's focus on AAV vectors carrying specific transgenes reflects its strategy to address complex neurological disorders with targeted gene-based therapies. The company's target segments include patients with neurological and psychiatric diseases requiring innovative treatment options. CombiGene AB's development pipeline centers on epilepsy treatment using NPY and Y2 receptor transgenes. The firm's approach involves creating therapies that combine multiple biological components to address disease mechanisms more effectively. Larkberget is one of the most popular companies on Eulerpool.